FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011941691> ?p ?o ?g. }

• W3011941691 endingPage "1349" @default.
• W3011941691 startingPage "1342" @default.
• W3011941691 abstract "Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation (HCT) that is traditionally diagnosed using Baltimore or modified Seattle criteria. Whereas the Baltimore criteria require the presence of hyperbilirubinemia (bilirubin ≥2 mg/dL) for a diagnosis of VOD/SOS, the modified Seattle criteria do not. Before approval by the US Food and Drug Administration, defibrotide was available in the United States through an expanded-access study (T-IND). The T-IND protocol initially required post-HCT diagnosis of VOD/SOS by the Baltimore criteria or biopsy but was later amended to include patients diagnosed using the modified Seattle criteria. This post hoc analysis examined the incidence of VOD/SOS with a bilirubin level <2 mg/dL before and after Day 21 post-HCT in T-IND patients enrolled following the amendment allowing for diagnosis by the modified Seattle criteria. Survival of adult and pediatric patients with or without hyperbilirubinemia and with or without multiorgan dysfunction (MOD) was also evaluated. Of 803 post-HCT patients with VOD/SOS enrolled following the protocol amendment, 181 (23%) had a bilirubin level <2 mg/dL and would not have been diagnosed if hyperbilirubinemia was required. The bilirubin level at diagnosis was <2 mg/dL in 165 of 331 patients (50%) diagnosed by the modified Seattle criteria and in 16 of 23 patients (70%) diagnosed by biopsy. VOD/SOS with a bilirubin level <2 mg/dL was more common in pediatric patients (29%), although it also occurred in adult patients (15%). Patients with hyperbilirubinemia had lower Day 100 survival (54% versus 87% in patients with bilirubin <2 mg/dL) and a higher incidence of MOD (41% versus 26% in patients with bilirubin <2 mg/dL). The incidence of treatment-emergent adverse events and serious adverse events was lower in patients with a bilirubin level <2 mg/dL. These results indicate that anicteric VOD/SOS occurs in both adult and pediatric patients post-HCT and can be diagnosed before and after Day 21 in both groups. The worse survival in patients with bilirubin ≥2 mg/dL suggests that requiring hyperbilirubinemia may result in a progressed disease stage associated with worse outcomes. Taken together, these results highlight the importance of awareness and the possibility of VOD/SOS in the absence of elevated bilirubin level." @default.
• W3011941691 created "2020-03-23" @default.
• W3011941691 creator A5031745226 @default.
• W3011941691 creator A5043526996 @default.
• W3011941691 creator A5072449563 @default.
• W3011941691 creator A5078683084 @default.
• W3011941691 creator A5079103223 @default.
• W3011941691 creator A5081252933 @default.
• W3011941691 date "2020-07-01" @default.
• W3011941691 modified "2023-09-27" @default.
• W3011941691 title "Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients" @default.
• W3011941691 cites W1966771497 @default.
• W3011941691 cites W1972172571 @default.
• W3011941691 cites W1993783426 @default.
• W3011941691 cites W2005419063 @default.
• W3011941691 cites W2021713360 @default.
• W3011941691 cites W2037010003 @default.
• W3011941691 cites W2066216766 @default.
• W3011941691 cites W2148164607 @default.
• W3011941691 cites W2180061107 @default.
• W3011941691 cites W2396687607 @default.
• W3011941691 cites W2793137791 @default.
• W3011941691 cites W2803440649 @default.
• W3011941691 cites W2803655366 @default.
• W3011941691 cites W2805170187 @default.
• W3011941691 cites W2809534462 @default.
• W3011941691 cites W2884218159 @default.
• W3011941691 cites W2885952230 @default.
• W3011941691 cites W2887878162 @default.
• W3011941691 cites W2977696805 @default.
• W3011941691 doi "https://doi.org/10.1016/j.bbmt.2020.03.011" @default.
• W3011941691 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8407521" @default.
• W3011941691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32200121" @default.
• W3011941691 hasPublicationYear "2020" @default.
• W3011941691 type Work @default.
• W3011941691 sameAs 3011941691 @default.
• W3011941691 citedByCount "17" @default.
• W3011941691 countsByYear W30119416912020 @default.
• W3011941691 countsByYear W30119416912021 @default.
• W3011941691 countsByYear W30119416912022 @default.
• W3011941691 countsByYear W30119416912023 @default.
• W3011941691 crossrefType "journal-article" @default.
• W3011941691 hasAuthorship W3011941691A5031745226 @default.
• W3011941691 hasAuthorship W3011941691A5043526996 @default.
• W3011941691 hasAuthorship W3011941691A5072449563 @default.
• W3011941691 hasAuthorship W3011941691A5078683084 @default.
• W3011941691 hasAuthorship W3011941691A5079103223 @default.
• W3011941691 hasAuthorship W3011941691A5081252933 @default.
• W3011941691 hasBestOaLocation W30119416911 @default.
• W3011941691 hasConcept C120665830 @default.
• W3011941691 hasConcept C121332964 @default.
• W3011941691 hasConcept C126322002 @default.
• W3011941691 hasConcept C141071460 @default.
• W3011941691 hasConcept C187212893 @default.
• W3011941691 hasConcept C2777408962 @default.
• W3011941691 hasConcept C2777513400 @default.
• W3011941691 hasConcept C2777712501 @default.
• W3011941691 hasConcept C2778456037 @default.
• W3011941691 hasConcept C2780895475 @default.
• W3011941691 hasConcept C2911091166 @default.
• W3011941691 hasConcept C61511704 @default.
• W3011941691 hasConcept C71924100 @default.
• W3011941691 hasConcept C90924648 @default.
• W3011941691 hasConceptScore W3011941691C120665830 @default.
• W3011941691 hasConceptScore W3011941691C121332964 @default.
• W3011941691 hasConceptScore W3011941691C126322002 @default.
• W3011941691 hasConceptScore W3011941691C141071460 @default.
• W3011941691 hasConceptScore W3011941691C187212893 @default.
• W3011941691 hasConceptScore W3011941691C2777408962 @default.
• W3011941691 hasConceptScore W3011941691C2777513400 @default.
• W3011941691 hasConceptScore W3011941691C2777712501 @default.
• W3011941691 hasConceptScore W3011941691C2778456037 @default.
• W3011941691 hasConceptScore W3011941691C2780895475 @default.
• W3011941691 hasConceptScore W3011941691C2911091166 @default.
• W3011941691 hasConceptScore W3011941691C61511704 @default.
• W3011941691 hasConceptScore W3011941691C71924100 @default.
• W3011941691 hasConceptScore W3011941691C90924648 @default.
• W3011941691 hasIssue "7" @default.
• W3011941691 hasLocation W30119416911 @default.
• W3011941691 hasLocation W30119416912 @default.
• W3011941691 hasOpenAccess W3011941691 @default.
• W3011941691 hasPrimaryLocation W30119416911 @default.
• W3011941691 hasRelatedWork W2157889301 @default.
• W3011941691 hasRelatedWork W2750010053 @default.
• W3011941691 hasRelatedWork W2751030399 @default.
• W3011941691 hasRelatedWork W2782257368 @default.
• W3011941691 hasRelatedWork W2786352895 @default.
• W3011941691 hasRelatedWork W2791058406 @default.
• W3011941691 hasRelatedWork W3028999888 @default.
• W3011941691 hasRelatedWork W4226404904 @default.
• W3011941691 hasRelatedWork W4288657936 @default.
• W3011941691 hasRelatedWork W4319263277 @default.
• W3011941691 hasVolume "26" @default.
• W3011941691 isParatext "false" @default.
• W3011941691 isRetracted "false" @default.
• W3011941691 magId "3011941691" @default.
• W3011941691 workType "article" @default.